Organoidsciences Ltd. (KOSDAQ:476040)

Market Cap	258.27B
Revenue (ttm)	2.55B
Net Income (ttm)	-13.83B
Shares Out	6.58M
EPS (ttm)	-2,392.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	291,385
Average Volume	740,407
Open	41,600
Previous Close	41,350
Day's Range	38,400 - 42,350
52-Week Range	23,000 - 52,000
Beta	n/a
RSI	47.15
Earnings Date	Mar 27, 2026

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476040

Financial Performance

In 2024, Organoidsciences's revenue was 1.95 billion, an increase of 22.77% compared to the previous year's 1.59 billion. Losses were -11.25 billion, -70.93% less than in 2023.